Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
Status:
Active, not recruiting
Trial end date:
2022-12-18
Target enrollment:
Participant gender:
Summary
This study is to find out if the combination of CC-122 (an investigational agent) and
Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are
responsible for maintaining the body's immune response).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute